Assessing Coupang (CPNG) Valuation After Cross Border Growth Wins With US Health Brands

Recent news around Kate’s Real Food and Healthy Origins using Coupang (CPNG) to reach customers in South Korea and Taiwan has drawn renewed attention to how its platform supports cross border growth for consumer brands.

See our latest analysis for Coupang.

The cross border wins with Kate’s Real Food and Healthy Origins arrive at a time when Coupang’s share price has been under pressure, with a 30 day share price return of 14.58% decline and a 90 day share price return of 32.04% decline, even though the three year total shareholder return of 20.82% is still positive. Recent momentum has been fading compared with the longer term picture.

If this kind of e commerce expansion has your attention, it could be a good moment to widen your watchlist with our screen of 22 top founder-led companies.

With Coupang shares falling over the past year despite revenue and net income growth, along with a sizeable gap to analyst targets and some intrinsic value estimates, you have to ask: is pessimism overdone, or is the market already baking in future growth?

Most Popular Narrative: 42% Undervalued

With Coupang at $18.05 versus a narrative fair value of $31.09, the current price sits well below what this widely followed view considers reasonable, setting up a very different story from the recent share price slide.

Ongoing investments in automation, AI, and logistics technology are already driving major improvements in operational efficiency and gross margins, and management sees significant further upside as these technologies are scaled; over time, this is likely to result in continued margin expansion and growth in earnings.

Read the complete narrative.

Curious how this earnings story is built. The narrative focuses on revenue expansion, higher margins, and a premium future earnings multiple. It is useful to see which precise assumptions push fair value that far above today’s price.

Result: Fair Value of $31.09 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this hinges on Coupang containing regulatory fallout from the data breach and avoiding prolonged losses in newer markets like Taiwan, which could pressure margins and earnings power.

Find out about the key risks to this Coupang narrative.

Another Angle On Valuation

The earlier narrative leans on future earnings power to argue Coupang is undervalued at $18.05, but its current P/E of 84.5x tells a very different story. That is far above the North American Multiline Retail average of 18.5x, the peer average of 30.4x, and even our fair ratio of 35.8x.

Such a wide gap suggests the market is already pricing in a lot of future success, which raises the risk if those expectations do not fully play out. As an investor, you have to decide which signal carries more weight: the discounted cash flow view or the rich P/E today?

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment clearly split between DCF optimism and a rich P/E, it makes sense to move quickly and review the full picture yourself, starting with 2 key rewards and 1 important warning sign.

Ready for more investing ideas?

If Coupang’s mixed signals have you thinking harder about where to put fresh capital to work, do not stop here. Broaden your search with focused stock ideas.

• Target potential mispricings by scanning our list of 53 high quality undervalued stocks that pair solid fundamentals with prices that may not fully reflect their qualities.
• Build a steadier income stream by reviewing 13 dividend fortresses, where companies combine higher yields with an emphasis on sustaining their payouts.
• Sleep easier by checking out 80 resilient stocks with low risk scores, highlighting businesses our models score as more resilient when it comes to financial and business risk.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com